0.7755

1.33% 0.0102

Atyr Pharma Inc (ATYR)

Overview News Price History Discussions Forecast

Atyr Pharma Inc stock is traded at $0.7755, with a volume of 1.53M. It is up +1.33% in the last 24 hours and up +7.29% over the past month. aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Previous Close:

$0.7653

Open:

$0.7579

24h Volume:

1.53M

Relative Volume:

0.15

Market Cap:

$75.99M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-5.87%

1M Performance:

+7.29%

6M Performance:

-85.72%

1Y Performance:

-74.32%

1-Day Range:

$0.7579

$0.795

1-Week Range:

$0.7579

$0.8354

52-Week Range:

$0.64

$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name

Atyr Pharma Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(858) 731-8389

Address

10240 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ATYR's Discussions on Twitter

Compare ATYR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATYR Atyr Pharma Inc	0.7755	74.99M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-18-25	Initiated	Leerink Partners	Outperform
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight
Sep-05-24	Initiated	Jefferies	Buy
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform
Sep-21-21	Initiated	Piper Sandler	Overweight
May-10-21	Initiated	Laidlaw	Buy
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Initiated	ROTH Capital	Buy
Mar-02-20	Initiated	Oppenheimer	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	Citigroup	Buy
Jun-01-15	Initiated	JP Morgan	Overweight

View All

Atyr Pharma Inc Stock (ATYR) Latest News

Dec 11, 2025

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - GlobeNewswire

Dec 11, 2025

Dec 09, 2025

Healthy Upside Potential: Atyr Pharma Inc (ATYR) - Setenews

Dec 09, 2025

Dec 08, 2025

ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Morningstar

Dec 08, 2025

Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - Louisiana First News

Dec 08, 2025

Shareholders that lost money on aTyr Pharma, Inc.(ATYR) - GlobeNewswire

Dec 08, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Bluefield Daily Telegraph

Dec 08, 2025

ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma - GlobeNewswire

Dec 08, 2025

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Dec 08, 2025

ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com

Dec 08, 2025

ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - marketscreener.com

Dec 08, 2025

Dec 07, 2025

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile

Dec 07, 2025

Dec 06, 2025

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire

Dec 06, 2025

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire Inc.

Dec 06, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile

Dec 06, 2025

Dec 05, 2025

מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.

Dec 05, 2025

ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, - GlobeNewswire

Dec 05, 2025

aTyr Pharma Receives Nasdaq Deficiency Notice - TipRanks

Dec 05, 2025

Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class ActionATYR - Your Wyoming Link

Dec 05, 2025